CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Updated clinical classification of pulmonary hypertension A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Diagnostic Performance of Angiogram-Derived Fractional Flow Reserve: A Pooled Analysis of 5 Prospective Cohort Studies Combined Assessment of Stress Myocardial Perfusion Cardiovascular Magnetic Resonance and Flow Measurement in the Coronary Sinus Improves Prediction of Functionally Significant Coronary Stenosis Determined by Fractional Flow Reserve in Multivessel Disease T and small protrusion (TAP) vs double kissing crush technique: Insights from in-vitro models Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial

Review Article2013 Dec 24;62(25 Suppl):D34-41.

JOURNAL:J Am Coll Cardiol. Article Link

Updated clinical classification of pulmonary hypertension

Simonneau G, Gatzoulis MA, Adatia I et al. Keywords: CHD; HAART; HIV; IFN; PAH; PAP; PH; PH due to chronic lung diseases; PH due to left heart disease; POPH; PPHN; PVR; SCD; Sch-PAH; TGF; TKI; chronic thromboembolic pulmonary hypertension; congenital heart disease; highly active antiretroviral therapy; human immunodeficiency virus; interferon; persistent pulmonary hypertension of the newborn; portopulmonary hypertension; pulmonary arterial hypertension; pulmonary arterial pressure; pulmonary hypertension; pulmonary vascular resistance; schistosomiasis-associated PAH; sickle cell disease; tumor growth factor; tyrosine kinase inhibitor

FULL TEXT PDF